Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-17T10:19:47.654Z Has data issue: false hasContentIssue false

Clostridioides difficile toxin testing and positivity in Manitoba, Canada

Published online by Cambridge University Press:  19 June 2020

Christiaan H. Righolt
Affiliation:
Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
Geng Zhang
Affiliation:
Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
Gregory W. Hammond
Affiliation:
Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
Philippe Lagace-Wiens
Affiliation:
Shared Health, Clinical Microbiology, Saint-Boniface Hospital, Winnipeg, Manitoba, Canada
Salaheddin M. Mahmud*
Affiliation:
Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
*
Author for correspondence: Salaheddin Mahmud, E-mail: Salah.Mahmud@gmail.com
Rights & Permissions [Opens in a new window]

Abstract

We assessed Clostridioides difficile toxin testing and positivity for all patients in Manitoba hospitals during June 2016–November 2018. The testing rate was 30 per 10,000 patient bed days (95% confidence interval [CI], 30–31) and the incidence rate was 3.5 per 10,000 patient bed days (95% CI, 3.3–3.7). The context of testing is essential to the interpretation of data among jurisdictions.

Information

Type
Concise Communication
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.
Figure 0

Table 1.Number and Crude Rate of C. difficile Toxin Testing and Positivity According to Gender, Age Group, and Year